Abstract
The Wilms tumor antigen, WT1, is expressed at high levels in various types of leukemia and solid tumors, including lung, breast, colon cancer and soft tissue sarcomas. The WT1 protein has been found to be highly immunogenic, and spontaneous humoral and cytotoxic T-cell responses have been detected in patients suffering from leukemia. Furthermore, major histocompatibility complexes class I- and II-restricted WT1 peptide epitopes have been shown to elicit immune responses in patients with WT1-expressing tumors. As a consequence, WT1 has become an attractive target for anticancer immunotherapy. In this study, we investigated the feasibility of generating WT1-specific T cells for adoptive immunotherapy after allogeneic stem cell transplantation. We analyzed the incidence of T cells specific for WT1 peptide epitopes in cancer patients and healthy volunteers. It is noted that we could generate WT1-specific responses in nine of ten healthy volunteer donors and established T-cell clones specific for two WT1-derived peptide epitopes. These in vitro expanded WT1-specific T cells effectively lysed WT1-expressing tumor cell lines, indicating the potential clinical impact of ex vivo expanded donor-derived WT1-specific T cells for adoptive immunotherapy after allogeneic stem cell transplantation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bader P, Sörensen J, Jarisch A, Weber G, Kreyenberg H, Esser R et al. Allogeneic stem cell transplantation in children and adolescents with high-risk alveolar rhabdomyosarcoma. Bone Marrow Transplant 2007; 39 (Suppl 1): 74.
Weber G, Kuci S, Karbach J, Willasch A, Kreyenberg H, Klingebiel T et al. WT1-specific T-cells as a therapeutic tool for cancer immunotherapy after stem cell transplantation. Bone Marrow Transplant 2008; 41 (Suppl 1): 300.
Bader P, Kreyenberg H, Hoelle W, Dueckers G, Handgretinger R, Lang P et al. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy? J Clin Oncol 2004; 22: 1696–1706.
Van Driessche A, Gao L, Stauss HJ, Ponsaerts P, Van Bockstaele DR, Berneman ZN et al. Antigen-specific cellular immunotherapy of leukemia. Leukemia 2005; 19: 1863–1871.
Greiner J, Dohner H, Schmitt M . Cancer vaccines for patients with acute myeloid leukemia—definition of leukemia-associated antigens and current clinical protocols targeting these antigens. Haematologica 2006; 91: 1653–1661.
Barrett AJ, Rezvani K . Translational mini-review series on vaccines: peptide vaccines for myeloid leukaemias. Clin Exp Immunol 2007; 148: 189–198.
Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms’ tumor locus. Cell 1990; 60: 509–520.
Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, Bruns GA . Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature 1990; 343: 774–778.
Loeb DM, Evron E, Patel CB, Sharma PM, Niranjan B, Buluwela L et al. Wilms’ tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation. Cancer Res 2001; 61: 921–925.
Gillmore R, Xue SA, Holler A, Kaeda J, Hadjiminas D, Healy V et al. Detection of Wilms’ tumor antigen-specific CTL in tumor-draining lymph nodes of patients with early breast cancer. Clin Cancer Res 2006; 12: 34–42.
Oji Y, Miyoshi S, Maeda H, Hayashi S, Tamaki H, Nakatsuka S et al. Overexpression of the Wilms’ tumor gene WT1 in de novo lung cancers. Int J Cancer 2002; 100: 297–303.
Makita M, Hiraki A, Azuma T, Tsuboi A, Oka Y, Sugiyama H et al. Antilung cancer effect of WT1-specific cytotoxic T lymphocytes. Clin Cancer Res 2002; 8: 2626–2631.
Koesters R, Linnebacher M, Coy JF, Germann A, Schwitalle Y, Findeisen P et al. WT1 is a tumor-associated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxic T cells. Int J Cancer 2004; 109: 385–392.
Wilsher M, Cheerala B . WT1 as a complementary marker of malignant melanoma: an immunohistochemical study of whole sections. Histopathology 2007; 51: 605–610.
Nakatsuka S, Oji Y, Horiuchi T, Kanda T, Kitagawa M, Takeuchi T et al. Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol 2006; 19: 804–814.
Gaiger A, Reese V, Disis ML, Cheever MA . Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood 2000; 96: 1480–1489.
Gaiger A, Carter L, Greinix H, Carter D, McNeill PD, Houghton RL et al. WT1-specific serum antibodies in patients with leukemia. Clin Cancer Res 2001; 7 (3 Suppl): 761s–765s.
Scheibenbogen C, Letsch A, Thiel E, Schmittel A, Mailaender V, Baerwolf S et al. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 2002; 100: 2132–2137.
Smith MA, Morton CL, Phelps D, Girtman K, Neale G, Houghton PJ . SK-NEP-1 and Rh1 are Ewing family tumor lines. Pediatr Blood Cancer 2008; 50: 703–706.
Kreuzer KA, Saborowski A, Lupberger J, Appelt C, Na IK, le Coutre P et al. Fluorescent 5′-exonuclease assay for the absolute quantification of Wilms’ tumour gene (WT1) mRNA: implications for monitoring human leukaemias. Br J Haematol 2001; 114: 313–318.
Cilloni D, Gottardi E, De Micheli D, Serra A, Volpe G, Messa F et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 2002; 16: 2115–2121.
Rezvani K, Brenchley JM, Price DA, Kilical Y, Gostick E, Sewell AK et al. T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms’ tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization. Clin Cancer Res 2005; 11 (24 Part 1): 8799–8807.
Chaise C, Buchan SL, Rice J, Marquet J, Rouard H, Kuentz M et al. DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance. Blood 2008; 112: 2956–2964.
Oka Y, Udaka K, Tsuboi A, Elisseeva OA, Ogawa H, Aozasa K et al. Cancer immunotherapy targeting Wilms’ tumor gene WT1 product. J Immunol 2000; 164: 1873–1880.
Oka Y, Elisseeva OA, Tsuboi A, Ogawa H, Tamaki H, Li H et al. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms’ tumor gene (WT1 ) product. Immunogenetics 2000; 51: 99–107.
Rezvani K, Grube M, Brenchley JM, Sconocchia G, Fujiwara H, Price DA et al. Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood 2003; 102: 2892–2900.
Ho WY, Nguyen HN, Wolfl M, Kuball J, Greenberg PD . In vitro methods for generating CD8+T-cell clones for immunotherapy from the naive repertoire. J Immunol Methods 2006; 310: 40–52.
Rezvani K, Yong AS, Savani BN, Mielke S, Keyvanfar K, Gostick E et al. Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood 2007; 110: 1924–1932.
Bellantuono I, Gao L, Parry S, Marley S, Dazzi F, Apperley J et al. Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. Blood 2002; 100: 3835–3837.
Asemissen AM, Keilholz U, Tenzer S, Muller M, Walter S, Stevanovic S et al. Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1. Clin Cancer Res 2006; 12: 7476–7482.
Bednarek MA, Sauma SY, Gammon MC, Porter G, Tamhankar S, Williamson AR et al. The minimum peptide epitope from the influenza virus matrix protein. Extra and intracellular loading of HLA-A2. J Immunol 1991; 147: 4047–4053.
Scheibenbogen C, Lee KH, Stevanovic S, Witzens M, Willhauck M, Waldmann V et al. Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay. Int J Cancer 1997; 71: 932–936.
DiBrino M, Tsuchida T, Turner RV, Parker KC, Coligan JE, Biddison WE . HLA-A1 and HLA-A3 T cell epitopes derived from influenza virus proteins predicted from peptide binding motifs. J Immunol 1993; 151: 5930–5935.
Karbach J, Gnjatic S, Pauligk C, Bender A, Maeurer M, Schultze JL et al. Tumor-reactive CD8+ T-cell clones in patients after NY-ESO-1 peptide vaccination. Int J Cancer 2007; 121: 2042–2048.
Blomberg K, Granberg C, Hemmila I, Lovgren T . Europium-labelled target cells in an assay of natural killer cell activity. I. A novel non-radioactive method based on time-resolved fluorescence. J Immunol Methods 1986; 86: 225–229.
Pritchard-Jones K, Fleming S, Davidson D, Bickmore W, Porteous D, Gosden C et al. The candidate Wilms’ tumour gene is involved in genitourinary development. Nature 1990; 346: 194–197.
Mundlos S, Pelletier J, Darveau A, Bachmann M, Winterpacht A, Zabel B . Nuclear localization of the protein encoded by the Wilms’ tumor gene WT1 in embryonic and adult tissues. Development 1993; 119: 1329–1341.
Maurer U, Brieger J, Weidmann E, Mitrou PS, Hoelzer D, Bergmann L . The Wilms’ tumor gene is expressed in a subset of CD34+ progenitors and downregulated early in the course of differentiation in vitro. Exp Hematol 1997; 25: 945–950.
Baird PN, Simmons PJ . Expression of the Wilms’ tumor gene (WT1) in normal hemopoiesis. Exp Hematol 1997; 25: 312–320.
Carpentieri DF, Nichols K, Chou PM, Matthews M, Pawel B, Huff D . The expression of WT1 in the differentiation of rhabdomyosarcoma from other pediatric small round blue cell tumors. Mod Pathol 2002; 15: 1080–1086.
Sebire NJ, Gibson S, Rampling D, Williams S, Malone M, Ramsay AD . Immunohistochemical findings in embryonal small round cell tumors with molecular diagnostic confirmation. Appl Immunohistochem Mol Morphol 2005; 13: 1–5.
Fernandez JE, Concha A, Aranega A, Ruiz-Cabello F, Cabrera T, Garrido F . HLA class I and II expression in rhabdomyosarcomas. Immunobiology 1991; 182: 440–448.
Prados J, Melguizo C, Fernandez JE, Carrillo E, Marchal JA, Boulaiz H et al. Induction of drug resistance in embryonal rhabdomyosarcoma treated with conventional chemotherapy is associated with HLA class I increase. Neoplasma 2006; 53: 226–231.
Feuchtinger T, Matthes-Martin S, Richard C, Lion T, Fuhrer M, Hamprecht K et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 2006; 134: 64–76.
Mailander V, Scheibenbogen C, Thiel E, Letsch A, Blau IW, Keilholz U . Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia 2004; 18: 165–166.
Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H et al. Induction of WT1 (Wilms’ tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 2004; 101: 13885–13890.
Morita S, Oka Y, Tsuboi A, Kawakami M, Maruno M, Izumoto S et al. A phase I/II trial of a WT1 (Wilms’ tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data. Jpn J Clin Oncol 2006; 36: 231–236.
Rezvani K, Yong AS, Mielke S, Savani BN, Musse L, Superata J et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008; 111: 236–242.
Acknowledgements
This work was supported by ‘Patenschaftsmodell’ of the University of Frankfurt/Main, Germany (GW) and is a sub-project of TranSaRNet, Translational Sarcoma Research Network of the Bundesministerium für Bildung und Forschung, Germany (PB).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Weber, G., Karbach, J., Kuçi, S. et al. WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantation. Leukemia 23, 1634–1642 (2009). https://doi.org/10.1038/leu.2009.70
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2009.70
Keywords
This article is cited by
-
Detection of relapse after hematopoietic stem cell transplantation in childhood by monitoring of WT1 expression and chimerism
Journal of Cancer Research and Clinical Oncology (2015)
-
Common Ewing sarcoma-associated antigens fail to induce natural T cell responses in both patients and healthy individuals
Cancer Immunology, Immunotherapy (2014)
-
Quantification of minimal residual disease levels by flow cytometry at time of transplant predicts outcome after myeloablative allogeneic transplantation in ALL
Bone Marrow Transplantation (2013)
-
Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant
Leukemia (2013)
-
Improved outcome following allogeneic stem cell transplantation in chronic myeloid leukemia is associated with higher expression of BMI-1 and immune responses to BMI-1 protein
Leukemia (2011)